On target to dual block RAS?

Angiology
Dimitris P PapadopoulosThomas K Makris

Abstract

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are thought to possess cardioprotective, cerebroprotective, and nephroprotective properties. Both classes of agents can prevent or reverse endothelial dysfunction and atherosclerosis, thereby potentially reducing the risk of cardiovascular events. Such a reduction has been shown with angiotensin-converting enzyme inhibitors in patients with coronary artery disease, but no such data are scarce with angiotensin receptor blockers (Valsartan in Acute Myocardial Infarction study). Both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been shown to reduce damage in target organs, such as the heart and kidney, and to decrease cardiovascular mortality and morbidity in patients with congestive heart failure. These drugs (especially angiotensin receptor blockers) may successfully prevent atrial fibrillation and play a protective role in metabolic syndrome. In some clinical settings, combined therapy angiotensin-converting enzyme inhibitors with angiotensin receptor blocker (double blockade of the renin-angiotensin- aldosterone system) may appear the most effective.

References

Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Jan 11, 2002·Lancet·P SleightUNKNOWN Heart Outcomes Prevention Evaluation (HOPE) Study
Oct 24, 2002·Journal of the American College of Cardiology·Aldo P MaggioniUNKNOWN Val-HeFT Investigators (Valsartan Heart Failure Trial)
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jun 21, 2003·Stroke; a Journal of Cerebral Circulation·Joachim SchraderUNKNOWN Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group
Aug 21, 2003·Biochemical and Biophysical Research Communications·Jeanette M WoodMartin P Bedigian
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Jan 24, 2004·Journal of Thrombosis and Thrombolysis·Seema A KothariPritesh J Gandhi
Apr 20, 2004·Journal of the American College of Cardiology·Albert FournierLeonardo Fernandez
Aug 6, 2004·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Trefor MorganRobert Jeffrey MacInnis
Oct 7, 2004·Current Medical Research and Opinion·Michel E Bertrand
Feb 18, 2005·Journal of Hypertension·Karin A M Jandeleit-DahmMark E Cooper
Apr 13, 2005·Blood Pressure·Peter TrenkwalderUNKNOWN Study on COgnition and Prognosis in the Elderly (SCOPE)
May 4, 2005·Acta Diabetologica·P Sleight
May 11, 2005·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·G GrassiG Mancia
May 12, 2005·The Journal of Clinical Hypertension·Samy I McFarlaneJames R Sowers
Jul 28, 2005·Current Opinion in Nephrology and Hypertension·Cristina Sierra, Alejandro de la Sierra
Aug 18, 2005·The Journal of Clinical Hypertension·William J Elliott
Aug 30, 2005·American Journal of Hypertension·R FerrariC Ceconi
Aug 30, 2005·American Journal of Hypertension·Stéphane Laurent
Mar 22, 2006·Expert Opinion on Therapeutic Targets·Dimitris P Papadopoulos, Vasilios Papademetriou
Apr 8, 2006·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Mark E CooperMerlin C Thomas
Sep 19, 2006·The New England Journal of Medicine·UNKNOWN DREAM Trial InvestigatorsRury R Holman
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Dominik N Müller, Friedrich C Luft

❮ Previous
Next ❯

Citations

May 6, 2010·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Sivarajan KumarasamyBina Joe
Apr 15, 2011·Vascular Health and Risk Management·Giuliano Tocci, Massimo Volpe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
Christian WernerMichael Böhm
Expert Review of Cardiovascular Therapy
Amir Ravandi, Koon K Teo
Future Cardiology
Lars Køber, Christian Torp-Pedersen
Vascular Health and Risk Management
Bodh I Jugdutt
© 2021 Meta ULC. All rights reserved